Literature DB >> 25475458

Residual arrhythmogenic foci predict recurrence in long-standing persistent atrial fibrillation patients after sinus rhythm restoration ablation.

Toshiya Kurotobi1, Yoshihisa Shimada2, Naoto Kino2, Kazato Ito2, Daisuke Tonomura2, Kentaro Yano2, Chiharu Tanaka2, Masataka Yoshida2, Takao Tsuchida2, Histohi Fukumoto2.   

Abstract

BACKGROUND: The mechanism of persistent atrial fibrillation (AF) is multifactorial, and arrhythmogenic foci (AMF) might be involved in the occurrence of persistent AF. In this study, we examined the electrophysiological features of AMF during and immediately after ablation, and evaluated the relationship between the presence and number of residual AMF on the risk of AF recurrence after a vigorous sinus rhythm restoration ablation in patients with long-standing persistent AF.
METHODS: The study consisted of 117 consecutive patients with persistent AF who underwent catheter ablation (CA). We performed direct cardioversion to restore sinus rhythm before the pulmonary vein (PV) isolation and at the end of the CA. Then we evaluated the features of the AMF inducible with isoproterenol and the pacing-based AF inducibility.
RESULTS: After the completion of ablation, AF could still be induced in 37 of 117 patients (31.6%). Spontaneous PV AMF during CA were observed in 104 of 117 patients (91%), and non-PV AMF in 63 of 117 (54%). Residual non-PV AMF were significantly associated with the pacing-based AF inducibility and an enlarged left atrial volume. In the multivariate analysis, the AF duration (1.01 [range, 1.00-1.02] months; P = 0.012), left atrial volume (1.01 [range, 1.01-1.02] mm; P = 0.006), and residual AMF (3.95 [range, 1.32-11.8] yes, no; P = 0.004) were independent risk factors for recurrent AF.
CONCLUSIONS: Residual AMF are associated with an increased long-term AF recurrence after sinus rhythm restoration ablation for long-standing persistent AF.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25475458     DOI: 10.1016/j.cjca.2014.10.013

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  How does fibrosis promote atrial fibrillation persistence: in silico findings, clinical observations, and experimental data.

Authors:  Stanley Nattel
Journal:  Cardiovasc Res       Date:  2016-04-30       Impact factor: 10.787

2.  Pharmacological Tests in Atrial Fibrillation Ablation.

Authors:  Jean-Baptiste Gourraud; Jason G Andrade; Laurent Macle; Blandine Mondésert
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

Review 3.  Very Long-Term Results Of Atrial Fibrillation Ablation Confirm That This Therapy Is Really Effective.

Authors:  Cristina Tutuianu; Judit Szilagy; Robert Pap; László Sághy
Journal:  J Atr Fibrillation       Date:  2015-08-31

4.  Arrhythmogenic triggers associated with an autonomic response from a posteroseptal region after extensive ablation in a patient with long-standing atrial fibrillation.

Authors:  Naoto Kino; Toshiya Kurotobi; Kazato Ito; Daisuke Tonomura; Kentaro Yano; Yoshihisa Shimada
Journal:  HeartRhythm Case Rep       Date:  2015-02-12

5.  Determinants of new wavefront locations in cholinergic atrial fibrillation.

Authors:  Caroline H Roney; Fu Siong Ng; Michael T Debney; Christian Eichhorn; Arun Nachiappan; Rasheda A Chowdhury; Norman A Qureshi; Chris D Cantwell; Jennifer H Tweedy; Steven A Niederer; Nicholas S Peters; Edward J Vigmond
Journal:  Europace       Date:  2018-11-01       Impact factor: 5.214

6.  Three-dimensional Integrated Functional, Structural, and Computational Mapping to Define the Structural "Fingerprints" of Heart-Specific Atrial Fibrillation Drivers in Human Heart Ex Vivo.

Authors:  Jichao Zhao; Brian J Hansen; Yufeng Wang; Thomas A Csepe; Lidiya V Sul; Alan Tang; Yiming Yuan; Ning Li; Anna Bratasz; Kimerly A Powell; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Raul Weiss; Orlando P Simonetti; John D Hummel; Vadim V Fedorov
Journal:  J Am Heart Assoc       Date:  2017-08-22       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.